Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic

World Allergy Organization Journal

Mario Morais-Almeida¹  Ignacio J. Ansotegui²  Bryan Martin³  Alessandro Fiocchi³  Pascal Demoly⁴  Jonathan Berstein⁵  Mario Sánchez-Borges⁵  José Antonio Ortega-Martell⁶  Liang Lu Wang⁷  Yoon-Seok Chang⁸  Gary Wong⁹  Jean-François Fontaine^1,10  Manana Chikhladze^1,11  Philip Rouadi^1,12  Giovanni Passalacqua^1,13  Marco Caminati^1,14  Luciana Kase Tanno^1,15  James Sublett^1,16  David B. Peden^1,17  Motohiro Ebisawa^1,18  Luis R. Caraballo^1,19  Anahí Yáñez^2,20  Sandra N. González-Díaz^2,21  Gianenrico Senna^2,22  Michael Levin^2,23 

[1] Corresponding author. Division of Allergy, Department of Pulmonology, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, 371, av. du Doyen Gaston Giraud, 34295, Montpellier, France.;Rheumatology, Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, 75013, Paris, France;University Hospital of Montpellier, Montpellier, France;WHO Collaborating Centre on Scientific Classification Support, Montpellier, France;Allergy Centre, CUF Descobertas Hospital, Lisbon, Portugal;Allergy and Clinical Immunology Department, Centro Medico Docente la Trinidad and Clinica El Avila, Caracas, Venezuela;Department of Allergy, Peking Union Medical College Hospital, Beijing, China;Department of Internal Medicine, Division of Immunology/Allergy Section at the University of Cincinnati Medical Center, USA;Department of Otolaryngology-Head and Neck Surgery, Eye and Ear University Hospital, Beirut, Lebanon;Department of Paediatrics, Chinese University of Hong Kong, Hong Kong;Division Paediatric Allergology, University of Cape Town, Cape Town, South Africa;;Division of Allergy, Immunology &Département des Maladies Allergiques et Respiratoires, University Hospital of Reims, Reims, France;Hospital Sírio-Libanês, Brazil;INAER-Investigaciones en Alergia y Enfermedades Respiratorias, Buenos Aires, Argentina;Institute for Immunological Research, University of Cartagena, Cartagena de Indias, Colombia;Medical Faculty at Akaki Tsereteli State University, Tskaltubo, KuTaisi, Georgia;Medicine and Pediatrics, The Ohio State University in Columbus, Ohio, USA;Predictive and Preventive Medicine Research Unit, Multifactorial and Systemic Diseases Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy;School of Medicine, Autonomous University of Hidalgo State, Pachuca, Hidalgo, Mexico;Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico;University Hospital of Montpellier, Montpellier, France;

关键词: Allergy;    Allergen immunotherapy;    Asthma;    Biological agents;    Coronavirus;    COVID-19;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: The COVID-19 outbreak brought an unprecedented challenge to the world. Knowledge in the field has been increasing exponentially and the main allergy societies have produced guidance documents for better management of allergic patients during this period. However, few publications so far have provided real-life data from the allergy community concerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international survey on the management of allergic patients during the current pandemic. Methods: We performed an online survey undertaken to reach out the worldwide allergy community by e-mail and social media. The web-based questionnaire contained 24 questions covering demographic data from the participants, clinical practice during this period, and questions related to the new international classification and coding tools addressed for COVID-19. It was circulated for 8 weeks and had anonymous and volunteer context. Results: Data are presented for 635 participants from 78 countries of all continents. Allergists with long-term professional experience were the main audience. As expected, we received many responses as “I have no data” or “I don't know” to the questions of the survey. However, most with more experience on managing allergic patients during the pandemic agreed that patients suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments (inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of contracting COVID-19 infection including severe presentations. Conclusion: The data presented are a starting point in the process of getting feedback on all the recommendations provided by the allergy societies; it could also be the basis of new strategies to support health professionals while new COVID-19 specific treatments and vaccines are being explored. The information here presented intends to be helpful to the community but represents a course of action in a highly specific situation due to the state of emergency, and it should be helpful to health systems.

【 授权许可】

Unknown